Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
66 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND Lenalidomide [TREATMENT] | Open Studies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Condition: B-cell Lymphoma
Intervention: Drug: Lenalidomide
2 Recruiting Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
Condition: T-cell Lymphoma
Intervention: Drug: Lenalidomide
3 Recruiting Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Lenalidomide
4 Recruiting Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide
5 Recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
6 Recruiting Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Lenalidomide/Rituximab
7 Recruiting Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab (GA101)
8 Recruiting Study of Ibrutinib in Combination With Rituximab and Lenalidomide
Conditions: Lymphoma;   Follicular Lymphoma (FL)
Interventions: Drug: Lenalidomide;   Drug: Rituximab;   Drug: Ibrutinib
9 Not yet recruiting Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Conditions: B Cell Lymphoma;   Lymphoma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Rituximab
10 Recruiting Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Rituximab
11 Recruiting Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide, Ibrutinib, Rituximab
12 Not yet recruiting Evaluation of the Immune Restoration Potential Of Lenalidomide
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Lenalidomide
13 Recruiting Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma
Conditions: Follicular Lymphoma Patients (Phase IB);   Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
Intervention: Drug: Lenalidomide and GA101
14 Recruiting Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Placebo
15 Recruiting Maintenance Lenalidomide in Lymphoma
Condition: Lymphoma
Intervention: Drug: Lenalidomide
16 Recruiting Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Conditions: T-cell Lymphomas;   Relapsed or Refractory
Interventions: Drug: Carfilzomib;   Drug: Romidepsin;   Drug: Lenalidomide
17 Recruiting A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
18 Recruiting A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: MOR00208;   Drug: Lenalidomide
19 Recruiting Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: Brentuximab vedotin;   Drug: Lenalidomide
20 Recruiting A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Condition: Relapsed/Refractory Mantle Cell Lymphoma.
Interventions: Drug: Lenalidomide;   Drug: Ibrutinib;   Drug: Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.